Outcome of patients hospitalized for Covid‐19 and exposure to angiotensin‐converting enzyme inhibitors and angiotensin‐receptor blockers in France: Results of the ACECoV study

Autor:	Guillaume Moulis, Guillaume Martin-Blondel, Sandrine Charpentier, Agnès Sommet, Pierre Delobel, Margaux Lafaurie
Přispěvatelé:	Service de Pharmacologie Médicale et Clinique, CHU Toulouse [Toulouse]-Centre d'Investigation Clinique, Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service des maladies infectieuses et tropicales [Toulouse], Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Service des Urgences (TOULOUSE - Urgences), Service de Médecine Interne [Purpan], CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Université de Caen Normandie (UNICAEN), Normandie Université (NU), Centre régional de pharmacovigilance de Grenoble [CHU Grenoble], Centre Hospitalier Universitaire [Grenoble] (CHU), Service Pharmacologie Clinique [CHU Toulouse], Pôle Santé publique et médecine publique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre d'investigation clinique de Toulouse (CIC 1436), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Pôle Santé publique et médecine publique [CHU Toulouse], Service Maladies infectieuses et tropicales [CHU Toulouse], Pôle Inflammation, infection, immunologie et loco-moteur [CHU Toulouse] (Pôle I3LM Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), PINIER, CHRISTINE
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	Male MESH: Hypertension / complications pharmacoepidemiology MESH: COVID-19 / drug therapy Angiotensin-Converting Enzyme Inhibitors MESH: Hospitalization Disease 030226 pharmacology & pharmacy SARS‐CoV‐2 law.invention Cohort Studies MESH: Aged 80 and over 0302 clinical medicine law [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases MESH: COVID-19 / enzymology Pharmacology (medical) MESH: Respiration Artificial MESH: Cohort Studies MESH: Cardiovascular Diseases / complications ComputingMilieux_MISCELLANEOUS MESH: Treatment Outcome Aged 80 and over education.field_of_study Angiotensin Receptor Antagonists biology MESH: Peptidyl-Dipeptidase A / drug effects Intensive care unit 3. Good health Hospitalization MESH: Peptidyl-Dipeptidase A / metabolism MESH: Angiotensin Receptor Antagonists / adverse effects Treatment Outcome Cardiovascular Diseases Cohort Hypertension [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases Population study Female angiotensin‐receptor blockers France medicine.symptom medicine.medical_specialty Angiotensins Critical Care MESH: COVID-19 / mortality Population Subgroup analysis Inflammation Peptidyl-Dipeptidase A MESH: Angiotensin-Converting Enzyme Inhibitors / adverse effects angiotensin‐converting enzyme inhibitors 03 medical and health sciences MESH: Critical Care COVID‐19 Internal medicine Renin–angiotensin system medicine Humans cardiovascular diseases education Propensity Score Aged Pharmacology MESH: Humans SARS-CoV-2 business.industry COVID-19 Angiotensin-converting enzyme MESH: Propensity Score medicine.disease Respiration Artificial MESH: Male Discontinuation COVID-19 Drug Treatment MESH: France Blood pressure Heart failure Propensity score matching biology.protein business MESH: Female 030217 neurology & neurosurgery
Zdroj:	Fundamental & Clinical Pharmacology Fundamental and Clinical Pharmacology Fundamental and Clinical Pharmacology, Wiley, 2021, Fundamental & Clinical Pharmacology, 35 (1), pp.194-203. ⟨10.1111/fcp.12613⟩ Fundamental and Clinical Pharmacology, Wiley, 2021, Fundamental & Clinical Pharm acology, 35 (1), pp.192-193. ⟨10.1111/fcp.12637⟩ Fundamental & Clinical Pharmacology, 2021, Fundamental & Clinical Pharmacology, 35 (1), pp.194-203. ⟨10.1111/fcp.12613⟩
ISSN:	1472-8206 0767-3981
DOI:	10.1111/fcp.12637
Popis:	International audience; Data are lacking on the impact of ACEI/ARB exposure on unfavorable outcome in the population of patients hospitalized for COVID‐19 with hypertension/cardiovascular disease, particularly in Europe. The ACE‐CoV study was designed to assess this question. The study was conducted in the Covid‐Clinic‐Toul cohort, which contains data about all patients hospitalized at Toulouse University hospital, France with a SARS‐CoV‐2 infection since March, 2020. We selected the patients with a history of cardiovascular disease (heart failure or coronary disease) and/or arterial hypertension. We conducted a subgroup analysis in patients with arterial hypertension. ACEI/ARB exposures at admission were assessed. The outcome was composite: admission to intensive care unit, need of mechanical ventilation or death during the 14 days after admission to hospital. We used logistic regression models with propensity scores (PS) weighted by overlap weighting (OW) and inverse probability of treatment weighting (IPTW). Between March 2020 and April 20, 2020, the Covid‐Clinic‐Toul included 263 patients. Among them, 111 were included in the ACE‐CoV study population. In OW‐PS‐adjusted analyses, the association of exposure to ACEIs or ARBs with outcome occurrence was OR: 1.56 (95% CI: 0.73–3.33). It was 0.99 (95% CI: 0.68–1.45) for ACEIs and 1.64 (95% CI: 0.77–3.50) for ARBs. Analyses with weighting by the IPTW‐PS method gave similar results. Results were similar when considering the subgroup of patients with arterial hypertension. The ACE‐CoV study found no association between exposure to ACEIs or ARBs and unfavorable outcome in hospitalized patients for COVID‐19 with a history of cardiovascular disease/arterial hypertension.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b24f27b39587cffd0a47de8cd57662a Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.